We were delighted to talk to Milind Javle (University of Texas MD Anderson Cancer Center, Houston, TX, US) about the use of infigratinib for the treatment of patients with previously treated advanced cholangiocarcinoma (Clinical Trial Identifier: NCT02150967).
The abstract ‘Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement’ (ABSTRACT NUMBER: 265) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
- What is the mechanism of action of infigratinib? (0:12)
- Could you please give us an overview of the phase II BGJ398 study of infigratinib and its findings? (0:33)
- What will be the next steps in the clinical development of infigratinib? (2:13)
- What are the treatment options for cholangiocarcinoma (CCA) after progression on first-line gemcitabine-based therapy? (3:17)
- Could you give us a brief overview of the clinical development of infigratinib in the treatment of CCA and its likely impact on treatment paradigms in the future? (3:50)
Disclosures: Milind Javle discloses funding/ research support from Incyte, QED, Basilea, Taiho, Astra Zeneca, Merck, EMD Serono, Novartis, Eli Lilly, Meclun and GSK.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
Share this Video
Related Videos In Gastrointestinal Oncology
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Jean-Luc Van Laethem, ASCO GI 2021: Pembrolizumab for Advanced Hepatocellular Carcinoma
We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) around pembrolizumab therapy in patients with previously untreated advanced hepatocellular carcinoma (Clinical Trial Identifier: NCT02702414). The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!